top of page


Venture Capital


Connecticut, USA and London, UK

Deal Date

December 2021

Deal Size



About the Manager

New Science Ventures ("NSV") is a Connecticut and London-based venture capital firm that invests in companies in the life sciences and information technology sectors. In both sectors, NSV targets companies which leverage breakthrough science to create extraordinary value and significant investment upside. Such technologies are typically already protected as patented intellectual property, and NSV seeks to build strong management teams that can deploy these innovations to the global market need they address.

NSV was founded in 2004 by Managing Partner Somu Subramaniam and Partner Tom Lavin. NSV has invested capital in more than 50 companies since it began. Today, the business has over $900 million of assets under management.

Investment Approach:

New Science Ventures

  • Invest in companies with differentiated value propositions with patience and continued support of these companies through their value inflection points

  • Seek out and build strong management teams that fit the companies’ stage of development, employing “virtual” business models as much as possible

  • Focus on fundamental, science-based innovation with strong intellectual property protection

  • Focus on the company-specific context and be willing to adopt contrarian views

  • Go where the science is - many portfolio companies are  outside the traditional Tech and Life Science spaces

  • Look for right syndicate partners – willing to lead, follow, or be sole investors

About the Deal


Investment Amount

$5 - $7 million



A senior redeemable preferred equity interest in an SPV that is backed by specific GP Commitments and carried interests from several existing fund vehicles. VPC are redeemed from the investment upon the achievement of the greater of an IRR and MOIC hurdle.

LIGHT-GREY-ICONS-Capital Protection.png

Capital Protection

VPC's investment is significantly over-collateralised with a diversified pool of 38 underlying portfolio company exposures.

The Manager's Use of Proceeds


To refinance an existing debt facility and fund growth-related expenses

bottom of page